The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling

Most patients with multiple myeloma treated with current therapies, including immunomodulatory drugs, eventually develop relapsed/refractory disease. Clinical activity of lenalidomide relies on degradation of Ikaros and the consequent reduction in IRF4 expression, both required for myeloma cell surv...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica
Main Authors: Díaz, Tania, Rodríguez, Vanina, Lozano, Ester, Mena, Mari-Pau, Calderón, Marcos, Rosiñol, Laura, Martínez, Antonio, Tovar, Natalia, Pérez-Galán, Patricia, Bladé, Joan, Roué, Gaël, de Larrea, Carlos Fernández
Format: Artigo
Language:Inglês
Published: Ferrata Storti Foundation 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5622862/
https://ncbi.nlm.nih.gov/pubmed/28751557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.164632
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items